Sci Simple

New Science Research Articles Everyday

# Biology # Pathology

Understanding Canine Haemangiosarcoma: What Pet Owners Need to Know

A deep dive into canine haemangiosarcoma for dog owners.

C. Taylor, G.J. Barry, D.G. O’Neill, A. Guillén, P. Pickard, J. Labadie, D.C. Brodbelt

― 7 min read


Canine Haemangiosarcoma Canine Haemangiosarcoma Facts haemangiosarcoma and treatment options. Essential insights on canine
Table of Contents

Canine haemangiosarcoma is a type of cancer that occurs in dogs. This cancer starts in cells that line blood vessels or in certain blood cell-related tissues. It can show up in different parts of the body, but it most commonly affects the spleen, heart, liver, and skin. Think of it as a troublesome guest that refuses to leave your house (or, in this case, your dog's body) and creates a mess wherever it goes.

How Common is it?

The occurrence of this cancer in dogs can vary widely depending on the group of dogs being studied. Research in the UK suggests that around 0.007% to 0.25% of dogs may be affected by it. To put it simply, it's not something every dog will encounter, but it's more common than finding a unicorn in your backyard (though both are pretty rare).

How is it Diagnosed?

To determine if a dog has haemangiosarcoma, veterinarians rely on a detailed examination of tissue samples. This usually involves a Biopsy, which is when a small piece of tissue is removed and looked at under a microscope. This is akin to putting the cancer under a magnifying glass to see just how mischievous it really is.

Staging the Cancer

After a diagnosis, it's important to figure out how far the cancer has spread. This process is called staging. It looks at factors like how many Tumors are present, whether lymph nodes are involved, if there are any distant metastases (which is when the cancer spreads to other areas), and whether the tumor has burst. Based on this information, the cancer is classified into stages I, II, or III. Think of staging as setting up a dog's health report card.

Treatment Options

When it comes to treatment, Surgery is usually the main option. Doctors often remove the tumor if possible. In some cases, chemotherapy is also used to help fight the cancer. Picture it as a tag team of medical interventions, where the surgeon gets the first punch, and then the chemotherapy swoops in to finish the job.

Radiotherapy might not be the first choice for all cases, but it can help in some specific situations, especially for heart and skin tumors. It's like bringing in a special forces team for a tricky mission.

Prognosis

The outlook for dogs diagnosed with haemangiosarcoma can vary quite a bit. If a tumor is affecting the skin, dogs can live longer after treatment (from about 172 to 1189 days). However, if the heart is involved, the time might be much shorter (as low as 7 to 189 days). In simple terms, it's a mixed bag—some dogs do quite well while others have a tougher time.

Factors that influence how long a dog might live after diagnosis can be divided into non-modifiable and modifiable aspects. Non-modifiable factors include the dog's age, size of the tumor, stage, and where the tumor is located. Modifiable factors might consist of treatment options chosen and how well the dog responds to those treatments.

Survival Rates by Location

Survival rates also change depending on where in the body the cancer shows up. For example, dogs with tumors on the skin tend to have a better chance of survival compared to those with heart tumors. It's like picking your battles; sometimes, you just want to avoid the ones that feel like a losing game from the start.

The Role of Tumor Size

Interestingly, the size of the tumor can also impact how long a dog might survive. In skin tumors, smaller sizes generally lead to better survival. However, this doesn't seem to have the same effect for tumors on the spleen. It's as if the rules of the game change depending on where you're playing.

Breed Considerations

Certain dog breeds are more likely to get this type of cancer. Retrievers and Shepherds, for instance, might be on the higher risk list. However, how a dog's breed affects survival rates after diagnosis is less clear. For skin tumors, some breeds, like Whippets and Dalmatians, might do better than others. With this, it’s kind of like certain groups having better luck in life—some just seem to get the better end of the deal.

Male vs. Female

When looking at the effect of sex, research shows that male dogs seem to have a slightly shorter survival time than females. It’s like a gender rivalry, but we can’t really pin down why that’s the case.

The Role of Treatment

After surgery, chemotherapy might improve survival rates for some, though studies have shown mixed results. In general, the type of treatment pursued can have varying levels of impact on how long a dog survives.

Some dogs even receive alternative treatments, but not much evidence suggests these work wonders for increasing survival times. A little bit like hoping a magic potion will make everything better—that’s not how it usually works!

Understanding the Study Population

Research into this illness has mostly been conducted with small groups of dogs or through specialized referral centers. This means the results might not accurately represent dogs under regular veterinary care. Think of it like a fancy restaurant experience versus a home-cooked meal; one might seem superior, but it doesn’t reflect the everyday recipes in most kitchens.

Study Goals

This study aimed to gather data from regular veterinary practices to get a clearer perspective of survival times and influencing factors related to dogs diagnosed with haemangiosarcoma. The researchers thought it was likely that dogs with skin tumors would have the longest survival and that larger tumors would generally lead to shorter survival times.

Identifying Cases

To gather data, researchers looked at records from various veterinary clinics. They identified cases by searching for specific keywords related to haemangiosarcoma in the clinical notes. If a dog had a final clinical diagnosis of this cancer in their records, it was included in the study. It’s like finding a needle in a haystack but with the help of a metal detector.

Analyzing Survival Times

Once the dogs were identified, survival times were calculated from the first diagnosis until death—or until the study period ended. It’s much like keeping track of a dog’s birthday to see how long they live beyond their first "gotcha" day.

Factors Linked to Survival

Various factors were analyzed to see how they impacted survival. The researchers looked at everything from whether a dog underwent surgery to the size of the tumor and even the dog's age. It was like trying to find a magic formula for a longer life, but they found it was a bit of a puzzle.

Insights from the Study

From the study, key findings emerged. Dogs diagnosed with cutaneous (skin) haemangiosarcoma had a longer median survival time compared to those diagnosed with other forms. The data suggested that size did matter, with bigger tumors leading to a higher risk of death. Additionally, surgery appeared to give dogs a better fighting chance.

Differences in Survival Times

The overall survival time for this type of cancer was relatively short, averaging only about 9 days. Contrast this with skin tumors, which could offer a longer survival time. It seems like the location really plays a significant role in the overall game.

Euthanasia Considerations

Many pet owners face tough choices when it comes to treatment options and the potential for euthanasia. Factors like perceived quality of life and prognosis often weigh heavily on these decisions. It’s like being given a difficult puzzle with missing pieces—you can try to figure it out, but it might still be a shot in the dark.

Conclusion

Canine haemangiosarcoma is a complex cancer with varied implications depending on the tumor's location, size, and other factors. The study adds valuable information to help veterinarians and pet owners understand what to expect with this illness. Though it's a challenging situation, knowing more about it can help make more informed choices, leading to a better quality of life for our furry friends.

In the end, while we may not know exactly how long a dog might have after diagnosis, every day is a chance to wag a tail and enjoy life. And let’s face it—who wouldn’t want to sit on the couch, share some snacks, and binge-watch their favorite shows with their best buddy by their side?

Original Source

Title: Survival time and prognostic factors in dogs diagnosed with haemangiosarcoma in UK first opinion practice

Abstract: AbstractVisceral haemangiosarcoma is considered clinically aggressive in dogs, with perceived poor prognosis often leading to euthanasia at presentation. This study aimed to determine survival times and prognostic factors in dogs with haemangiosarcoma under first-opinion care. Dogs diagnosed with haemangiosarcoma in first-opinion practice in 2019 were identified in VetCompass electronic health records (EHRs) and manually examined to capture variables potentially associated with survival. Median survival time (MST) from diagnosis was calculated for the whole population and based on the primary tumour location. Binary logistic regression was used to explore differences between dogs that died on the day of diagnosis and those that survived [≥]1 day. Cox proportional hazards modelling explored factors associated with time to death in dogs that survived [≥]1 day. Across all haemangiosarcoma cases (n=788), overall MST was 9.0 days (95%CI:5.0-15.0, range: 0-1789) and proportional 1-year survival was 12.0% (95%CI:9.7-15.0%). Dogs with splenic (MST=4.0 days, 95%CI 0.0-9.0) and cutaneous haemangiosarcoma (MST=119.0 days,95%CI:85.0-248.0) had MST greater than 0 days. Male sex and increasing tumour size were associated with increased hazard of death while cutaneous location and surgery were associated with reduced hazard of death. A very short survival time was identified for haemangiosarcoma under first-opinion care. Although survival time was longest for cutaneous cases, the actualised prognosis was poor overall for haemangiosarcoma. This study provides valuable information for contextualised care and dialogues with clients in first-opinion practice.

Authors: C. Taylor, G.J. Barry, D.G. O’Neill, A. Guillén, P. Pickard, J. Labadie, D.C. Brodbelt

Last Update: 2024-12-14 00:00:00

Language: English

Source URL: https://www.biorxiv.org/content/10.1101/2024.12.07.627327

Source PDF: https://www.biorxiv.org/content/10.1101/2024.12.07.627327.full.pdf

Licence: https://creativecommons.org/licenses/by/4.0/

Changes: This summary was created with assistance from AI and may have inaccuracies. For accurate information, please refer to the original source documents linked here.

Thank you to biorxiv for use of its open access interoperability.

Similar Articles